CLINICAL_TRIALS
other
· 2026-04-03
Clinical Trial Update: Osimertinib In EGFR Mutant Lung Cancer [Phase 2]
Summary
A Phase 2 clinical trial evaluating osimertinib for EGFR-mutant non-small cell lung cancer is currently recruiting.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Dana-Farber Cancer Institute | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: RECRUITING